| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
94,749 |
76,902 |
$17.39M |
| 92134 |
|
178,023 |
150,954 |
$5.52M |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
9,090 |
8,670 |
$4.83M |
| J2778 |
Injection, ranibizumab, 0.1 mg |
16,142 |
12,988 |
$4.52M |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
182,087 |
174,931 |
$4.35M |
| J9035 |
Injection, bevacizumab, 10 mg |
62,220 |
50,408 |
$3.46M |
| 68761 |
|
44,405 |
25,467 |
$3.39M |
| 92235 |
|
57,007 |
56,704 |
$3.27M |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
100,912 |
93,194 |
$2.52M |
| 92250 |
|
57,253 |
56,606 |
$2.16M |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
54,529 |
54,434 |
$1.59M |
| 67228 |
|
6,963 |
5,788 |
$1.45M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
17,658 |
17,611 |
$1.12M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
34,125 |
32,874 |
$1.08M |
| 67210 |
|
3,660 |
3,020 |
$1.00M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
35,369 |
33,269 |
$834K |
| V2020 |
Frames, purchases |
54,244 |
54,088 |
$722K |
| 92133 |
|
25,070 |
24,923 |
$519K |
| 92136 |
|
12,103 |
11,460 |
$436K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
2,010 |
1,594 |
$430K |
| 92340 |
Fitting of spectacles, except for aphakia; monofocal |
36,560 |
36,344 |
$425K |
| 92083 |
|
19,577 |
19,186 |
$403K |
| 92015 |
Determination of refractive state |
79,195 |
79,098 |
$385K |
| 68810 |
|
3,363 |
2,770 |
$366K |
| 66821 |
|
3,161 |
2,657 |
$308K |
| J0178 |
Injection, aflibercept, 1 mg |
797 |
717 |
$280K |
| 92020 |
|
18,264 |
18,119 |
$242K |
| 92341 |
|
11,936 |
11,911 |
$209K |
| 67031 |
|
1,634 |
1,495 |
$143K |
| 68020 |
|
1,110 |
1,108 |
$82K |
| 92002 |
|
3,347 |
3,346 |
$70K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
927 |
912 |
$70K |
| 92201 |
|
5,013 |
4,852 |
$64K |
| 76514 |
|
6,268 |
6,206 |
$54K |
| 92242 |
|
698 |
690 |
$50K |
| 92226 |
|
2,021 |
1,491 |
$47K |
| 76512 |
|
1,502 |
1,205 |
$44K |
| 67800 |
|
731 |
726 |
$42K |
| J7999 |
Compounded drug, not otherwise classified |
1,970 |
1,821 |
$40K |
| 67820 |
|
1,550 |
1,522 |
$33K |
| 65205 |
|
828 |
822 |
$32K |
| 92060 |
|
1,131 |
1,113 |
$31K |
| 65778 |
|
1,095 |
1,053 |
$29K |
| 67700 |
|
572 |
569 |
$28K |
| 92025 |
|
1,503 |
1,481 |
$26K |
| 99205 |
Prolong outpt/office vis |
266 |
266 |
$22K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,163 |
1,122 |
$19K |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
32 |
24 |
$15K |
| 67108 |
|
14 |
12 |
$14K |
| 66982 |
|
26 |
26 |
$13K |
| 66761 |
|
72 |
52 |
$12K |
| 92225 |
|
410 |
316 |
$11K |
| 65855 |
|
110 |
82 |
$8K |
| 92202 |
|
859 |
853 |
$7K |
| 67938 |
|
52 |
52 |
$6K |
| 2022F |
|
2,343 |
2,238 |
$6K |
| 99215 |
Prolong outpt/office vis |
212 |
208 |
$6K |
| 92227 |
|
799 |
786 |
$2K |
| 67145 |
|
12 |
12 |
$1K |
| 99024 |
|
243 |
201 |
$802.17 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
1,809 |
1,726 |
$651.74 |
| V2103 |
Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens |
53 |
31 |
$435.13 |
| V2025 |
Deluxe frame |
14 |
14 |
$388.08 |
| V2100 |
Sphere, single vision, plano to plus or minus 4.00, per lens |
17 |
13 |
$219.60 |
| 76519 |
|
15 |
13 |
$153.08 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
16 |
14 |
$118.10 |
| 0517F |
|
60 |
59 |
$113.60 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
737 |
736 |
$106.40 |
| 92285 |
|
15 |
14 |
$47.39 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
56 |
56 |
$38.43 |
| 2023F |
|
328 |
307 |
$0.00 |
| 3072F |
|
600 |
600 |
$0.00 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
30 |
30 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
103 |
103 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
81 |
81 |
$0.00 |
| 5010F |
|
319 |
316 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
35 |
35 |
$0.00 |